Orbassano

• A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/ … Not authorised
  2022-500410-26-00 5 Cystic Fibrosis
• Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3 - CRYSTAL Pending
  2023-508062-15-00 5 Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
• A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending
  2024-514701-57-01 4 non Small Cell Lung Cancer
• A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma posit … Pending
  2024-515555-38-01 4 NON SMALL CELL LUNG CANCER
• Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending
  2024-518386-95-02 4 Non small-cell lung cancer
• Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with … Pending
  2024-519106-12-00 4 Patients with anaplastic lymphoma kinase positive (ALK+) locally advan
• A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel … Pending
  2024-519786-22-01 9 metastatic non-small cell lung cancer (NSCLC)
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC Pending
  2025-521971-29-00 5 Non Small Cell Lung Cancer (NSCLC)
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending
  2025-524040-35-00 5 Severe uncontrolled asthma
• Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv … Pending
  2025-524048-36-00 5 Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcin
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)
• A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending
  2025-524488-18-00 4 Muscle-invasive Bladder Cancer
• Symbiotic-Lung-14: A Study to Learn About the Study Medicine called PF-08634404 in Combination With Chemotherapy in Adult Participants With … Pending
  2025-524686-24-00 4 Small Cell Lung Cancer
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Recruiting
  2025-520565-51-00 5 2026-06-23 small cell lung cancer
• A clinical trial of MK-1084 and durvalumab in people with non-small cell lung cancer (MK-1084-015) Recruiting
  2025-522038-29-00 5 2026-06-16 Locally advanced, unresected (unresectable or medically inoperable or
• A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s … Recruiting
  2025-524843-11-00 4 2026-06-15 Non-Small Cell Lung Cancer
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting
  2025-523576-23-00 5 2026-06-12 Unresectable Stage III non-small cell lung cancer without progression
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting
  2025-524316-11-00 5 2026-06-11 Primary Progressive Multiple Sclerosis (PPMS)
• Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Recruiting
  2025-523947-36-00 4 2026-06-10 Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherap
• A Study to Learn about the Study Medicine called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive Stage Sma … Recruiting
  2025-523522-41-00 10 2026-06-01 Extensive-Stage Small Cell Lung Cancer
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma

Showing 1–24 of 208 trials